CN104145018B - 新型C5a结合性核酸 - Google Patents

新型C5a结合性核酸 Download PDF

Info

Publication number
CN104145018B
CN104145018B CN201380009020.9A CN201380009020A CN104145018B CN 104145018 B CN104145018 B CN 104145018B CN 201380009020 A CN201380009020 A CN 201380009020A CN 104145018 B CN104145018 B CN 104145018B
Authority
CN
China
Prior art keywords
nucleic acid
acid molecules
nox
present
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380009020.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104145018A (zh
Inventor
K·霍利戈
A·威特
K·布彻讷
C·马施
S·克鲁斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptarian Biotechnology Inc
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of CN104145018A publication Critical patent/CN104145018A/zh
Application granted granted Critical
Publication of CN104145018B publication Critical patent/CN104145018B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
CN201380009020.9A 2012-01-10 2013-01-10 新型C5a结合性核酸 Active CN104145018B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12000106 2012-01-10
EP12000106.0 2012-01-10
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12006960 2012-10-08
EP12006960.4 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (2)

Publication Number Publication Date
CN104145018A CN104145018A (zh) 2014-11-12
CN104145018B true CN104145018B (zh) 2019-05-10

Family

ID=48781063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380009020.9A Active CN104145018B (zh) 2012-01-10 2013-01-10 新型C5a结合性核酸

Country Status (18)

Country Link
US (5) US9518265B2 (enExample)
EP (1) EP2802660B1 (enExample)
JP (1) JP6415327B2 (enExample)
KR (1) KR102034203B1 (enExample)
CN (1) CN104145018B (enExample)
AU (2) AU2013209131A1 (enExample)
BR (1) BR112014016877B1 (enExample)
CA (1) CA2860806C (enExample)
DK (1) DK2802660T3 (enExample)
ES (1) ES2786007T3 (enExample)
IL (1) IL233516B (enExample)
IN (1) IN2014DN05665A (enExample)
MX (1) MX362061B (enExample)
PL (1) PL2802660T3 (enExample)
PT (1) PT2802660T (enExample)
RU (1) RU2645261C2 (enExample)
SG (2) SG11201403771SA (enExample)
WO (1) WO2013104540A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849323A (zh) 2013-10-28 2016-08-10 多茨设备公司 过敏原检测
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
MX2020012225A (es) 2018-05-17 2021-01-29 Procter & Gamble Sistemas y metodos para el analisis de la cobertura del cabello.
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
US11384357B2 (en) 2018-06-29 2022-07-12 The Procter And Gamble Company Aptamers for personal care applications
AU2019378732A1 (en) * 2018-11-12 2021-05-27 Aptarion Biotech Ag CXCL8 binding nucleic acids
WO2020214784A1 (en) 2019-04-16 2020-10-22 The Procter & Gamble Company Aptamers for odor control applications
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用
EP4620474A1 (en) 2024-03-20 2025-09-24 APTARION biotech AG Method of treating a disorder with a c5a inhibitor
WO2025196240A1 (en) 2024-03-20 2025-09-25 Aptarion Biotech Ag Method of treating a disorder with a c5a inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041271A1 (en) * 1998-02-12 1999-08-19 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
WO2005079363A2 (en) * 2004-02-12 2005-09-01 Archemix Corporation Aptamer therapeutics useful in the treatment of complement-related disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE469164T1 (de) 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
RU2394041C2 (ru) 2003-04-13 2010-07-10 Энзон Фармасьютикалз, Инк. Полимерные олигонуклеотидные пролекарства
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP1713509A2 (de) 2004-02-09 2006-10-25 Noxxon Pharma AG Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
JP2008526915A (ja) * 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト Ｃ５ａ受容体アンタゴニスト
PT1991275E (pt) 2006-03-08 2015-02-03 Archemix Llc Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
AU2007296054B2 (en) 2006-09-15 2013-03-28 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
US20100062436A1 (en) 2006-10-31 2010-03-11 Noxxon Pharma Ag Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
CN101809154A (zh) * 2007-09-24 2010-08-18 诺松制药股份公司 C5a结合核酸
CN102421350B (zh) 2009-03-11 2014-12-17 奥林巴斯医疗株式会社 图像处理系统、其外部装置及其图像处理方法
US20120065254A1 (en) 2009-03-23 2012-03-15 Noxxon Pharma Ag C5A binding nucleic acids and the use thereof
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
CA2824073A1 (en) * 2011-01-10 2012-07-19 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
AU2012325233A1 (en) 2011-10-21 2014-04-24 Noxxon Pharma Ag Glucagon binding nucleic acids
MX2014008456A (es) 2012-01-10 2014-11-25 Noxxon Pharma Ag Acidos nucleicos que enlazan especificamente a cgrp.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041271A1 (en) * 1998-02-12 1999-08-19 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
WO2005079363A2 (en) * 2004-02-12 2005-09-01 Archemix Corporation Aptamer therapeutics useful in the treatment of complement-related disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Axel Vater.Identification and characterisation of C5a-inhibiting biostable aptamers.《Molecular Immunology》.2010,第47卷第2290页. *
Identification and characterisation of C5a-inhibiting biostable aptamers;Axel Vater;《Molecular Immunology》;20101231;第47卷;第2290页 *

Also Published As

Publication number Publication date
US20180223285A1 (en) 2018-08-09
US20240384275A1 (en) 2024-11-21
WO2013104540A1 (en) 2013-07-18
PL2802660T3 (pl) 2020-07-27
US20250327082A1 (en) 2025-10-23
BR112014016877A2 (pt) 2019-10-29
DK2802660T3 (da) 2020-05-18
JP6415327B2 (ja) 2018-10-31
US20140364487A1 (en) 2014-12-11
US10590424B2 (en) 2020-03-17
US11492625B2 (en) 2022-11-08
CA2860806C (en) 2020-10-20
BR112014016877B1 (pt) 2022-03-15
MX2014008454A (es) 2015-02-05
CA2860806A1 (en) 2013-07-18
IN2014DN05665A (enExample) 2015-05-15
JP2015509705A (ja) 2015-04-02
AU2018271388B2 (en) 2021-03-11
EP2802660B1 (en) 2020-02-19
US12188021B2 (en) 2025-01-07
KR102034203B1 (ko) 2019-10-18
IL233516A0 (en) 2014-08-31
PT2802660T (pt) 2020-04-21
HK1198371A1 (en) 2015-04-10
EP2802660A1 (en) 2014-11-19
AU2013209131A1 (en) 2014-07-10
RU2014132708A (ru) 2016-02-27
CN104145018A (zh) 2014-11-12
SG11201403771SA (en) 2014-07-30
IL233516B (en) 2018-07-31
ES2786007T3 (es) 2020-10-08
AU2018271388A1 (en) 2018-12-20
MX362061B (es) 2019-01-07
RU2645261C2 (ru) 2018-02-19
KR20140111703A (ko) 2014-09-19
SG10201605594UA (en) 2016-09-29
US20210163946A1 (en) 2021-06-03
US9518265B2 (en) 2016-12-13

Similar Documents

Publication Publication Date Title
CN104145018B (zh) 新型C5a结合性核酸
CN103946381B (zh) Ngf适体及其应用
JP5798320B2 (ja) Ｃ５ａに結合する核酸
AU2011223527B2 (en) Aptamers to 4-1BB and their use in treating diseases and disorders
CA3024917A1 (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof
CN101702917A (zh) 一种调节核酸分子活性的方法
Nakamura et al. RNA plasticity and selectivity applicable to therapeutics and novel biosensor development
TW200831668A (en) Aptamer for midkine and use thereof
TWI500425B (zh) 對ｎｇｆ之適體及其用途
EP4373940A2 (en) Products and compositions
US20120065254A1 (en) C5A binding nucleic acids and the use thereof
EP4620474A1 (en) Method of treating a disorder with a c5a inhibitor
HK1198371B (en) New c5a binding nucleic acids
WO2025196240A1 (en) Method of treating a disorder with a c5a inhibitor
WO2024169907A1 (zh) 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途
US20070117768A1 (en) Anti-apoptotically active apatamers
CN119506291A (zh) 结合Tth DNA聚合酶的核酸适配体及其应用
HK1146296A (en) C5a binding nucleic acids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191012

Address after: Berlin

Patentee after: Aptarian biotechnology, Inc.

Address before: Berlin

Patentee before: Nozon Pharmaceutical Co., Ltd.

TR01 Transfer of patent right